Literature DB >> 8386663

Peptides of 23 residues or greater are required to stimulate a high affinity class II-restricted T cell response.

M Srinivasan1, S Z Domanico, P T Kaumaya, S K Pierce.   

Abstract

Helper T cells recognize fragments of antigen bound to the class II molecules on the surface of antigen-presenting cells. Naturally processed antigenic fragments have been isolated from the class II molecules and shown to be heterogeneous in length, ranging from 13 to 25 residues, and to vary at both the N and C termini. A 15-residue peptide in an extended conformation is predicted to fit in an open peptide-binding cleft of the class II molecules. Thus, the longer peptides observed bound to class II presumably have regions which reside outside the cleft. It is not known if the additional length contributes significantly to T cell activation. We have carried out a systematic analysis of the antigenicity of peptides of increasing length beyond the minimally defined T cell antigenic peptide. Here we show that the full functional activities of peptides representing the major antigenic determinant of the protein antigen, cytochrome c, minimally require that the peptides be 23 amino acids long. The long peptides do not require processing and are presented by purified class II molecules incorporated into synthetic membranes, indicating that such peptides associate directly with class II and require no additional cellular machinery for presentation. We also show that a hybrid peptide, 51 residues in length, containing a 29-residue cytochrome c peptide and a "promiscuous" peptide of tetanus toxoid, is more antigenic than the 23-residue peptide alone and significantly, does not require processing. Thus, the additional peptide length, although not predicted to bind in the peptide-binding groove of the MHC class II molecule, has a significant impact on the ability of the peptides to stimulate T cell responses maximally.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8386663     DOI: 10.1002/eji.1830230504

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

1.  Fine specificity and cross-clade reactivity of HIV type 1 Gag-specific CD4+ T cells.

Authors:  Philip J Norris; Howell F Moffett; Christian Brander; Todd M Allen; Kristin M O'Sullivan; Lisa A Cosimi; Daniel E Kaufmann; Bruce D Walker; Eric S Rosenberg
Journal:  AIDS Res Hum Retroviruses       Date:  2004-03       Impact factor: 2.205

Review 2.  The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?

Authors:  Craig L Slingluff
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

Review 3.  A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.

Authors:  Pravin T P Kaumaya
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Fine structure of a virus-encoded helper T-cell epitope expressed on FBL-3 tumor cells.

Authors:  T Shimizu; H Uenishi; Y Teramura; M Iwashiro; K Kuribayashi; H Tamamura; N Fujii; H Yamagishi
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

Review 5.  Peptide vaccines for hematological malignancies: a missed promise?

Authors:  Monica Bocchia; Marzia Defina; Lara Aprile; Anna Sicuranza
Journal:  Int J Hematol       Date:  2014-01-08       Impact factor: 2.490

6.  The utility and limitations of current Web-available algorithms to predict peptides recognized by CD4 T cells in response to pathogen infection.

Authors:  Francisco A Chaves; Alvin H Lee; Jennifer L Nayak; Katherine A Richards; Andrea J Sant
Journal:  J Immunol       Date:  2012-03-30       Impact factor: 5.422

7.  Development of a peptide-targeted, myocardial ischemia-homing, mesenchymal stem cell.

Authors:  Thomas J Kean; Lori Duesler; Randell G Young; Alisher Dadabayev; Andrey Olenyik; Marc Penn; Joseph Wagner; David J Fink; Arnold I Caplan; James E Dennis
Journal:  J Drug Target       Date:  2011-11-02       Impact factor: 5.016

8.  Peptide length significantly influences in vitro affinity for MHC class II molecules.

Authors:  Cathal O'Brien; Darren R Flower; Conleth Feighery
Journal:  Immunome Res       Date:  2008-11-26

9.  Determining the breadth of the respiratory syncytial virus-specific T cell response.

Authors:  Daniel S McDermott; Cory J Knudson; Steven M Varga
Journal:  J Virol       Date:  2013-12-26       Impact factor: 5.103

10.  Amino acid residues that flank core peptide epitopes and the extracellular domains of CD4 modulate differential signaling through the T cell receptor.

Authors:  D A Vignali; J L Strominger
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.